Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer
Autore:
Thor, AD; Liu, S; Edgerton, S; Moore, D; Kasowitz, KM; Benz, CC; Stern, DF; DiGiovanna, MP;
Indirizzi:
Northwestern Univ, Evanston Hosp, Dept Pathol, Evanston, IL 60201 USA Northwestern Univ Evanston IL USA 60201 pt Pathol, Evanston, IL 60201 USA Univ Calif San Francisco, Calif Pacific Med Ctr, San Francisco, CA 94143 USA Univ Calif San Francisco San Francisco CA USA 94143 ancisco, CA 94143 USA Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA Univ Calif San Francisco San Francisco CA USA 94143 ancisco, CA 94143 USA Yale Univ, Sch Med, New Haven, CT USA Yale Univ New Haven CT USAYale Univ, Sch Med, New Haven, CT USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 18, volume: 18, anno: 2000,
pagine: 3230 - 3239
SICI:
0732-183X(20000915)18:18<3230:A(POE(>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; FACTOR RECEPTOR; POINT MUTATION; NEU ONCOGENE; PROGNOSTIC FACTORS; CELLULAR-RESPONSE; ADJUVANT THERAPY; DOSE INTENSITY; MAMMARY-TUMORS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Thor, AD Northwestern Univ, Evanston Hosp, Dept Pathol, 2650 Ridge Ave, Evanston, IL 60201 USA Northwestern Univ 2650 Ridge Ave Evanston IL USA 60201 60201 USA
Citazione:
A.D. Thor et al., "Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer", J CL ONCOL, 18(18), 2000, pp. 3230-3239

Abstract

Purpose: We hypothesize that phosphorylated ErbB-2 (P-ErbB-2, identified by a novel antibody PN2A) may provide either more significant or additional prognostic marker data for breast cancer patients. This study was designed to compare the incidence and prognostic value of ErbB-2 (HER-2/neu) and P-ErbB-2 immunoexpression in archival breast cancer samples. Materials and Methods: Eight hundred sixteen invasive breast cancers with a median of 16.3 years of follow-up were immunostained for ErbB-2 (using antibody CB11) and P-ErbB-2 (using antibody PN2A). ErbB-2 and P-ErbB-2 data were compared with clinical, histologic, immunohistochemical, and outcome variables. Results: Of 816 primary breast cancers, 307 (38%) were positive for ErbB-2and 37(12% of ErbB-2 positive and 5% of the study population) expressed P-ErbB-2, P-ErbB-2 was not detected in ErbB-2-negative cases (n = 509). ErbB-2 immunohistochemical data were bimodal; patients with greater than or equal to 80% cellular expression had the shortest disease-free and disease-specific survival. P-ErbB-2 was associated with a higher percentage of ErbB-2-positive cells, a higher number of positive lymph nodes, and cellular proliferation. ErbB-2 and P-ErbB-2 were indicators of poor prognosis in node-positive patients in bath univariate and multivariate analyses. We found that either P-ErbB-2 expression or high (greater than or equal to 80%) ErbB-2 expression provided the most significant prognostic value in node-positive cases by multivariate analyses. There were too few P-ErbB-2-positive cases andevents in the node-negative patient group to allow statistical analysis ofp-ErbB-2 in that subgroup. Conclusion: PN2A immunostaining identified a subset (approximately 12% of ErbB-2-positive breast cancers) with activation (phosphorylation) of the receptor ErbB-2. P-ErbB-2 expression was strongly associated with higher levels of ErbB-2 expression (greater than or equal to 80%), although it was nota surrogate. Identification of cases with a high percentage of invasive breast cancer cells expressing ErbB-2 or determination of receptor activationvia P-ErbB-2 may provide additional prognostic value in node-positive breast cancers. (C) 2000 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 16:16:08